Table 6.

Univariable and Multivariable Analysis of Mortality Risk at Baseline and 6 Months After Commencing Chemotherapy

Survival Analysis at Baseline
	Univariable		Multivariable Model Excluding Liver and Spleen ECV		Multivariable Model Including Liver and Spleen ECV
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
NT-proBNP >1,800 ng/L	2.55 (1.76-3.72)	<0.001	1.43 (0.86-2.38)	0.170	1.65 (0.98-2.75)	0.058
Troponin T >40 ng/L	2.46 (1.69-3.58)	<0.001	1.49 (0.93-2.38)	0.100	1.35 (0.84-2.18)	0.210
dFLC >180 mg/L	1.76 (1.25-2.48)	0.001	1.58 (1.09-2.28)	0.014	1.45 (1.00-2.11)	0.050
Myocardial ECV	1.05 (1.03-1.07)	<0.001	1.04 (1.01-1.06)	0.001	1.03 (1.01-1.06)	0.009
Liver ECV	1.03 (1.01-1.05)	<0.001	—	—	1.03 (1.01-1.05)	0.001
Spleen ECV	1.01 (1.00-1.02)	0.244	—	—	0.99 (0.98-1.01)	0.347

Survival Analysis at 6 mo
	Univariable		Multivariable Model Excluding Change in Liver and Spleen ECV		Multivariable Model Including Change in Liver and Spleen ECV
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Hematologic response
CR	Ref.		Ref.		Ref.
VGPR	1.80 (0.61-5.37)	0.289	1.48 (0.44-4.98)	0.526	1.18 (0.34-4.03)	0.794
PR	3.42 (1.36-8.57)	0.009	2.37 (0.83-6.76)	0.106	1.40 (0.43-4.48)	0.576
NR	8.70 (3.08-24.59)	<0.001	7.32 (2.55-21.05)	<0.001	3.84 (1.17-12.56)	0.026
NT-proBNP response
Improvement	Ref.		Ref.		Ref.
Stable	1.65 (0.57-4.76)	0.352	1.76 (0.50-6.15)	0.377	1.00 (0.28-3.64)	0.994
Worse	2.84 (1.08-7.48)	0.034	1.51 (0.49-4.68)	0.478	0.95 (0.29-3.12)	0.928
Change in myocardial ECV	1.13 (1.07-1.19)	<0.001	1.14 (1.06-1.23)	<0.001	1.11 (1.02-1.20)	0.011
Change in liver ECV	1.13 (1.09-1.17)	<0.001	—	—	1.07 (1.01-1.13)	0.014
Change in spleen ECV	1.07 (1.04-1.11)	<0.001	—	—	1.03 (0.98-1.08)	0.198

CR = complete response; dFLC = difference in concentration between aberrant and uninvolved class of free light chains; NR = no response; PR = partial response; Ref. = reference; VGPR = very good partial response; other abbreviations as in Tables 2 and 4.